FDA
-
-
-
-
-
-
-
Viking Therapeutics (VKTX) Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
-
-
-
-
-
-
-
Viking Therapeutics to Highlight Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023
-
-
-
-
-
-
-
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735
-
-
-
-
-
-
-
Viking Therapeutics (VKTX) Announces FDA's Clinical Hold on Phase 1b Trial of VK0214
-
-
-
-
-
-
-
Viking Therapeutics (VKTX) Announces Results from Phase 1 Clinical Trial of Novel Oral Thyroid Receptor Beta Agonist VK0214
-
-
-
-
-
-
-
Pre-Open 11/19: (MYOV) (MDCO) (VKTX) Higher (I) (KSS) (HD) Lower (more...)
-
-
-
-
-
-
-
Stifel Starts Viking Therapeutic (VKTX) at Buy
-
251,815 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All